| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sylvia L Asa, Ozgur Mete, Nicole D Riddle, Arie Perr. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1. Endocrine pathology. 2023-06-02. PMID:37268858. |
acromegaly was the presentation in 26 patients; 2 had central hyperthyroidism associated with growth hormone (gh) excess and one had significantly elevated prolactin (prl). |
2023-06-02 |
2023-08-14 |
Not clear |
| Junwei Guo, Wenhao Cao, Jinmei Luo, Rong Huang, Yi Xia. A retrospective study of the role of hypercapnia in patients with acromegaly. BMC pulmonary medicine. vol 23. issue 1. 2023-05-27. PMID:37244996. |
acromegaly is a multisystemic disease characterized by an excessive release of growth hormone (gh) and insulin-like growth factor-1. |
2023-05-27 |
2023-08-14 |
Not clear |
| Sara Sohail, Waqas Shafiq, Kashif Sajjad, Umal Azmat, Muhammad Atif Navee. Ectopic Acromegaly Secondary to Bronchial Tumour: A Case Report of Rare Occurrence. Journal of cancer & allied specialties. vol 7. issue 1. 2023-05-17. PMID:37197403. |
acromegaly is caused due to the unregulated and sustained overproduction of growth hormone (gh). |
2023-05-17 |
2023-08-14 |
Not clear |
| Nicholas Shoung, Ken K Y H. Managing Estrogen Therapy in the Pituitary Patient. Journal of the Endocrine Society. vol 7. issue 5. 2023-05-05. PMID:37143694. |
the route-dependent effects and potency of estrogen formulations are important considerations for optimizing the management of hypogonadal patients with pituitary disease, in particular gh deficiency and acromegaly. |
2023-05-05 |
2023-08-14 |
human |
| Paul Fellinger, Hannes Beiglböck, Georg Semmler, Lorenz Pfleger, Sabina Smajis, Clemens Baumgartner, Martin Gajdosik, Rodrig Marculescu, Greisa Vila, Yvonne Winhofer, Thomas Scherer, Michael Trauner, Alexandra Kautzky-Willer, Martin Krssak, Michael Krebs, Peter Wol. Increased GH/IGF-I axis activity relates with lower hepatic lipids and phosphor metabolism. The Journal of clinical endocrinology and metabolism. 2023-04-27. PMID:37104943. |
while data on acromegaly, a state of chronic growth hormone (gh)/insulin-like growth factor i(igf-i) excess, suggest an inverse relationship with intrahepatic lipid content (ihl), less is known about the impact of the gh/igf-i axis on ihl, lipid composition and phosphor metabolites in individuals without disorders of gh secretion. |
2023-04-27 |
2023-08-14 |
Not clear |
| Nunzia Prencipe, Giovanna Motta, Chiara M Crespi, Umberto Albert, Alessandro M Berton, Chiara Bona, Fabio Bioletto, Emanuele Varaldo, Daniela Cuboni, Valentina Gasco, Ezio Ghigo, Giuseppe Maina, Silvia Grottol. Psychiatric disorders and anger in patients with controlled acromegaly. Minerva endocrinology. 2023-04-06. PMID:37021924. |
acromegaly (acro) is a chronic rare disease caused by a pathological increase in growth hormone (gh) secretion. |
2023-04-06 |
2023-08-14 |
human |
| Juan Chen, Zhigao Xiang, Zhuo Zhang, Yan Yang, Kai Shu, Ting Le. Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly. Journal of clinical medicine. vol 12. issue 6. 2023-03-29. PMID:36983284. |
acromegaly is a chronic disease caused by the overproduction of growth hormone (gh) and accompanying insulin-like growth factor-1 (igf-1), which is often caused by gh-secreting pituitary adenomas. |
2023-03-29 |
2023-08-14 |
Not clear |
| Juan Chen, Zhigao Xiang, Zhuo Zhang, Yan Yang, Kai Shu, Ting Le. Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly. Journal of clinical medicine. vol 12. issue 6. 2023-03-29. PMID:36983284. |
here, we summarize the relevant literature concerning cognitive-behavioral research on acromegaly to demonstrate the impact of long-term impairment caused by gh and igf-1 on the cognitive behavior of patients. |
2023-03-29 |
2023-08-14 |
Not clear |
| Ana Filipa Martins, Mónica Santos, Francisco Rosári. Caloric restriction as a possible pitfall for persistent acromegaly follow-up - case report. BMC endocrine disorders. vol 23. issue 1. 2023-03-27. PMID:36973824. |
acromegaly diagnosis is established when plasma levels of igf-1 are increased and the oral glucose tolerance test (ogtt) with 75gr of glucose can't suppress growth hormone (gh) levels. |
2023-03-27 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
acromegaly is a disorder characterized by igf-1 excess due to autonomous gh secretion. |
2023-03-17 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
in individuals without acromegaly, igf-1 is not only influenced by gh secretion but is also sensitive to other factors including nutritional status, as evidenced by the inverted u-shaped association between bmi and igf-1; in low-weight individuals (bmi < 18.5 kg/m |
2023-03-17 |
2023-08-14 |
Not clear |
| Maria João Bugalho, Mariana Lopes-Pinto, Carlos Lemos, Ema Nobr. In Search of the Hyperglycemic Threshold Required to Induce Growth Hormone (GH) Suppression. Cureus. vol 15. issue 1. 2023-03-06. PMID:36874742. |
introduction according to the 2014 endocrine society clinical practice guideline on acromegaly, the confirmation of acromegaly diagnosis is established by finding a lack of suppression of growth hormone (gh) to < 1 ug/l following documented hyperglycemia during an oral glucose tolerance test. |
2023-03-06 |
2023-08-14 |
Not clear |
| Sher Bahadur Poudel, Ryan R Ruff, Gozde Yildirim, Manisha Dixit, Benoit Michot, Jennifer L Gibbs, Silvana Duran Ortiz, John J Kopchick, Thorsten Kirsch, Shoshana Yaka. Excess growth hormone triggers inflammation-associated arthropathy, subchondral bone loss, and arthralgia. The American journal of pathology. 2023-03-04. PMID:36870529. |
in humans, excess gh secretion due to pituitary adenoma, seen in patients with acromegaly, results in severe arthropathies. |
2023-03-04 |
2023-08-14 |
mouse |
| Cesar Luiz Boguszewski, Margaret Cristina da Silva Boguszewski, Wouter W de Herde. The science behind the relations among cancer, height, growth patterns and growth hormone axis. Endocrine-related cancer. 2023-02-13. PMID:36779772. |
in animal and human models, genetic defects associated with gh deficiency or resistance are associated with protection from tumor development, while risk of malignancies in acromegaly or in patients exposed to recombinant gh therapy has long been a matter of concern and scrutiny. |
2023-02-13 |
2023-08-14 |
human |
| Daniel G Henriques, Renan Lyra Miranda, Rômulo Sperduto Dezonne, Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Leila Chimelli, Leandro Kasuki, Elisa B Lamback, Alexandro Guterres, Monica R Gadelh. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36769196. |
acromegaly is a chronic systemic disease caused in the vast majority of cases by growth hormone (gh)-secreting adenoma, with surgery being the first-line treatment. |
2023-02-11 |
2023-08-14 |
Not clear |
| Shouan Zhu, Huanhuan Liu, Trent Davis, Craig R G Willis, Reetobrata Basu, Luke Witzigreuter, Stephen Bell, Nathaniel Szewczyk, Martin K Lotz, Marcheta Hill, Roberto J Fajardo, Patrick M O'Connor, Darlene E Berryman, John J Kopchic. Excessive growth hormone promotes joint degeneration and chondrocyte metabolic dysfunction in mice. Arthritis & rheumatology (Hoboken, N.J.). 2023-02-10. PMID:36762426. |
many patients with acromegaly, a hormonal disorder with excessive growth hormone (gh), report pain in joints. |
2023-02-10 |
2023-08-14 |
mouse |
| Rajesh Chhabra, Ashwani Kumar, R S Virk, Pinaki Dutta, Chirag Ahuja, Manju Mohanty, Sivashanmugam Dhandapan. Outcomes in pituitary adenoma causing acromegaly following endoscopic endonasal transsphenoidal surgery. Journal of neurosciences in rural practice. vol 13. issue 4. 2023-02-06. PMID:36743751. |
the objectives of the study were to study the analysis of outcomes after endoscopic endonasal transsphenoidal surgery (eetss) in acromegaly in terms of surgical complications, clinical improvement, endocrinological remission, achievement of prognostically critical growth hormone (gh) level, and requirement of additional treatment. |
2023-02-06 |
2023-08-14 |
Not clear |
| Madisyn Oxley, Heather Francis, Keisaku Sat. Growth hormone signaling in liver diseases: Therapeutic potentials and controversies. Seminars in liver disease. 2023-01-18. PMID:36652958. |
gh deficiency causes short stature or dwarfism, and excess gh causes acromegaly. |
2023-01-18 |
2023-08-14 |
Not clear |
| Ruixin Cao, Di Zhang, Haichang Xing, Mingyan Wang, Zhongshuo Lu, Bing Fa. Acromegaly with joint pain as an initial symptom: A case report. International journal of rheumatic diseases. 2023-01-17. PMID:36647758. |
acromegaly is caused by the long-term excessive secretion of growth hormone (gh) and insulin-like growth factor-1 (igf-1). |
2023-01-17 |
2023-08-14 |
Not clear |
| Artak Labadzhyan, Shlomo Melme. Molecular targets in acromegaly. Frontiers in endocrinology. vol 13. 2022-12-22. PMID:36545335. |
currently available medical therapies for patients with acromegaly bind to somatostatin receptors, gh receptor, or dopamine receptors, and lead to attainment of disease control in most patients. |
2022-12-22 |
2023-08-14 |
Not clear |